Platinum-resistant Fallopian Tube Cancer

Platinum-resistant Fallopian Tube Cancer is the indication for 3 drugs in DrugBank. It is covered by 7 curated, structured indications.

Also known as: Platinum-resistant Fallopian Cancer · platinum drug resistant Fallopian Tube Cancer · Platinum-Resistant Fallopian Tube Carcinoma · Platinum Resistant Fallopian Tube Cancer
Classified under: Neoplasms
Urogenital Diseases
Indicated drugs: Mirvetuximab soravtansine
Pembrolizumab
Relacorilant

What you can answer from here — as of October 22, 2026

3Indicated drugsWith each drug's targets and mechanism

Listed above

7Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

26Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Platinum-resistant Fallopian Tube Cancer share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.